Brief: Calidi Biotherapeutics And City Of Hope Provide Update On A Phase 1 Clinical Trial With CLD-101 Virotherapy In Patients With Recurrent High-Grade Glioma
26/03/2025 12:06
March 26 (Reuters) - Calidi Biotherapeutics Inc CLDI.A: CALIDI BIOTHERAPEUTICS AND CITY OF HOPE PROVIDE UPDATE ON A PHASE 1 CLINICAL TRIAL WITH CLD-101 VIROTHERAPY IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA Source text: ID:nGNX6cmSK4 Further company coverage: CLDI.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Calidi Biotherapeutics
See all newsBrief: Calidi Biotherapeutics Announces Strategic Partnership With Transferai
Brief: Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval
Brief: Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public Offering
Brief: Calidi Biotherapeutics Eliminates Chief Legal Officer Position - SEC Filing
Brief: Calidi Biotherapeutics Receives FDA Fast Track Designation For Cld-201 (Supernova), A First-In-Class Stem-Cell Loaded Viral Therapy For The Treatment Of Patients With Soft Tissue Sarcoma